Galectin Therapeutics reported 4.02 in Sales Revenues for its fiscal quarter ending in March of 2023.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Merck USD 16.6B 310M Jun/2026